EA202191745A1 - Катионные нейротоксины - Google Patents
Катионные нейротоксиныInfo
- Publication number
- EA202191745A1 EA202191745A1 EA202191745A EA202191745A EA202191745A1 EA 202191745 A1 EA202191745 A1 EA 202191745A1 EA 202191745 A EA202191745 A EA 202191745A EA 202191745 A EA202191745 A EA 202191745A EA 202191745 A1 EA202191745 A1 EA 202191745A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino acid
- acid modification
- toxin
- engineered
- relates
- Prior art date
Links
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 3
- 238000012986 modification Methods 0.000 abstract 3
- 241000193403 Clostridium Species 0.000 abstract 2
- 231100001102 clostridial toxin Toxicity 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
Abstract
Изобретение относится к сконструированному токсину клостридий, включающему по меньшей мере одну аминокислотную модификацию, где по меньшей мере одна указанная аминокислотная модификация способствует увеличению изоэлектрической точки (pI) сконструированного токсина клостридий до величины, которая по меньшей мере на 0,2 единицы выше, чем pI какого-либо другого идентичного токсина клостридий, не содержащего по меньшей мере одной указанной аминокислотной модификации. Настоящее изобретение также относится к применению соответствующего сконструированного токсина клостридий в терапии.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1312317.9A GB201312317D0 (en) | 2013-07-09 | 2013-07-09 | Cationic neurotoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191745A1 true EA202191745A1 (ru) | 2022-01-31 |
Family
ID=49033565
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690189A EA039105B1 (ru) | 2013-07-09 | 2014-07-09 | Катионные нейротоксины |
EA202191745A EA202191745A1 (ru) | 2013-07-09 | 2014-07-09 | Катионные нейротоксины |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690189A EA039105B1 (ru) | 2013-07-09 | 2014-07-09 | Катионные нейротоксины |
Country Status (24)
Country | Link |
---|---|
US (2) | US9920310B2 (ru) |
EP (2) | EP3943105A3 (ru) |
JP (4) | JP6850127B2 (ru) |
KR (3) | KR20240005140A (ru) |
CN (2) | CN112961227A (ru) |
AR (2) | AR096869A1 (ru) |
AU (1) | AU2014288953C1 (ru) |
CA (1) | CA2917009A1 (ru) |
DK (1) | DK3019190T3 (ru) |
EA (2) | EA039105B1 (ru) |
ES (1) | ES2881301T3 (ru) |
GB (1) | GB201312317D0 (ru) |
HK (1) | HK1222795A1 (ru) |
HU (1) | HUE055733T2 (ru) |
IL (3) | IL243330B (ru) |
MX (2) | MX2016000047A (ru) |
PL (1) | PL3019190T3 (ru) |
PT (1) | PT3019190T (ru) |
SA (1) | SA516370371B1 (ru) |
SG (2) | SG11201600150UA (ru) |
TW (3) | TWI694081B (ru) |
UA (1) | UA126889C2 (ru) |
WO (1) | WO2015004461A1 (ru) |
ZA (1) | ZA201801413B (ru) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
WO2016025626A2 (en) | 2014-08-12 | 2016-02-18 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specifity and methods for producing same |
PT3242884T (pt) | 2015-01-09 | 2021-04-22 | Ipsen Bioinnovation Ltd | Neurotoxinas catiónicas |
GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
FI3481852T3 (fi) * | 2016-07-08 | 2023-03-19 | Childrens Medical Center | Uusi botulinum-neurotoksiini ja sen johdannaisia |
TW201814045A (zh) * | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
EP3752128A1 (de) * | 2018-02-16 | 2020-12-23 | Bontana Therapies Gmbh | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
TWI825396B (zh) * | 2020-03-16 | 2023-12-11 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
WO2022073360A1 (zh) * | 2020-10-10 | 2022-04-14 | 广州东盛生物科技有限公司 | 构建新型冠状病毒疫苗的方法及其应用 |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
KR20230163470A (ko) | 2021-03-30 | 2023-11-30 | 입센 바이오팜 리미티드 | 통증 & 염증성 장애의 치료 |
CA3211472A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
CA3231083A1 (en) | 2021-09-16 | 2023-03-23 | Nicolae GRIGORE | Modified bont/a for use in the treatment of cervical dystonia |
KR20240067100A (ko) | 2021-09-23 | 2024-05-16 | 입센 바이오팜 리미티드 | 대상체의 안검 근육에 이환된 장애의 치료에 사용하기 위한 변형된 bont/a |
GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
WO2023075060A1 (ko) * | 2021-10-25 | 2023-05-04 | 비피메드(주) | 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물 |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
CN115819526A (zh) * | 2022-12-02 | 2023-03-21 | 海雅美生物技术(珠海)有限公司 | 一种重组肉毒杆菌神经毒素及其制备方法和应用 |
GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
DE122009000066I2 (de) | 1993-06-10 | 2010-12-30 | Allergan Inc | Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
WO1999058571A2 (de) | 1998-05-13 | 1999-11-18 | BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung |
JP4454152B2 (ja) | 1998-07-22 | 2010-04-21 | オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド | 二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物 |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
JP2004512004A (ja) * | 1999-05-12 | 2004-04-22 | ユナイテッド ステイツ アーミー メディカル リサーチ アンド マテリエル シーエムディー | ボツリヌス神経毒に対する組換えワクチン |
US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
ES2277854T5 (es) | 1999-08-25 | 2011-02-04 | Allergan, Inc. | Neurotoxinas recombinantes activables. |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
CA2501856A1 (en) | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
WO2006059093A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Fusion proteins |
RU2007136616A (ru) * | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
JP2008532549A (ja) * | 2005-03-15 | 2008-08-21 | アラーガン、インコーポレイテッド | 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素 |
DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
EP1926744B2 (en) | 2005-09-19 | 2018-10-24 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
CA2657460A1 (en) * | 2006-07-11 | 2008-09-04 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
WO2009014854A1 (en) * | 2007-07-26 | 2009-01-29 | Allergan, Inc. | Methods of activiting clostridial toxins |
WO2009015840A2 (en) * | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
US8445650B2 (en) * | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
RU2010120016A (ru) * | 2007-10-23 | 2011-11-27 | Аллерган, Инк. (Us) | Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов |
SG10202100698QA (en) * | 2008-12-31 | 2021-02-25 | Revance Therapeutics Inc | Injectable Botulinum Toxin Formulations |
GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
WO2010120766A1 (en) | 2009-04-14 | 2010-10-21 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
JP4900443B2 (ja) | 2009-09-30 | 2012-03-21 | 大日本印刷株式会社 | 色素増感型太陽電池 |
NZ703378A (en) * | 2010-05-20 | 2016-10-28 | Allergan Inc | Degradable clostridial toxins |
US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
US20120189677A1 (en) | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
JP6162135B2 (ja) * | 2011-11-09 | 2017-07-12 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 短縮された生物活性を示す神経毒 |
CN104736166B (zh) * | 2012-05-30 | 2018-02-16 | 哈佛大学校长及研究员协会 | 工程化的肉毒神经毒素 |
GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
-
2013
- 2013-07-09 GB GBGB1312317.9A patent/GB201312317D0/en not_active Ceased
-
2014
- 2014-07-09 DK DK14747697.2T patent/DK3019190T3/da active
- 2014-07-09 EP EP21167912.1A patent/EP3943105A3/en active Pending
- 2014-07-09 EA EA201690189A patent/EA039105B1/ru unknown
- 2014-07-09 TW TW103123643A patent/TWI694081B/zh active
- 2014-07-09 EA EA202191745A patent/EA202191745A1/ru unknown
- 2014-07-09 PL PL14747697T patent/PL3019190T3/pl unknown
- 2014-07-09 UA UAA201601094A patent/UA126889C2/uk unknown
- 2014-07-09 PT PT147476972T patent/PT3019190T/pt unknown
- 2014-07-09 HU HUE14747697A patent/HUE055733T2/hu unknown
- 2014-07-09 EP EP14747697.2A patent/EP3019190B1/en active Active
- 2014-07-09 US US14/903,458 patent/US9920310B2/en active Active
- 2014-07-09 SG SG11201600150UA patent/SG11201600150UA/en unknown
- 2014-07-09 MX MX2016000047A patent/MX2016000047A/es unknown
- 2014-07-09 CN CN202110239457.8A patent/CN112961227A/zh active Pending
- 2014-07-09 KR KR1020237044106A patent/KR20240005140A/ko active Application Filing
- 2014-07-09 SG SG10202005416PA patent/SG10202005416PA/en unknown
- 2014-07-09 TW TW109114599A patent/TWI776147B/zh active
- 2014-07-09 KR KR1020217040836A patent/KR102617830B1/ko active IP Right Grant
- 2014-07-09 KR KR1020167003051A patent/KR102340476B1/ko active IP Right Grant
- 2014-07-09 TW TW111118323A patent/TWI813291B/zh active
- 2014-07-09 AU AU2014288953A patent/AU2014288953C1/en active Active
- 2014-07-09 ES ES14747697T patent/ES2881301T3/es active Active
- 2014-07-09 CN CN201480043806.7A patent/CN105492020B/zh active Active
- 2014-07-09 JP JP2016524894A patent/JP6850127B2/ja active Active
- 2014-07-09 WO PCT/GB2014/052097 patent/WO2015004461A1/en active Application Filing
- 2014-07-09 CA CA2917009A patent/CA2917009A1/en active Pending
- 2014-07-10 AR ARP140102553A patent/AR096869A1/es unknown
-
2015
- 2015-12-24 IL IL243330A patent/IL243330B/en active IP Right Grant
-
2016
- 2016-01-07 SA SA516370371A patent/SA516370371B1/ar unknown
- 2016-01-07 MX MX2021006714A patent/MX2021006714A/es unknown
- 2016-09-20 HK HK16111009.8A patent/HK1222795A1/zh unknown
-
2018
- 2018-02-06 US US15/889,317 patent/US11034947B2/en active Active
- 2018-03-01 ZA ZA2018/01413A patent/ZA201801413B/en unknown
-
2019
- 2019-04-01 JP JP2019069960A patent/JP7360802B2/ja active Active
- 2019-11-19 IL IL270769A patent/IL270769B/en active IP Right Grant
-
2020
- 2020-04-24 AR ARP200101165A patent/AR118777A2/es unknown
- 2020-08-25 IL IL276915A patent/IL276915B/en unknown
-
2021
- 2021-12-21 JP JP2021206753A patent/JP7434263B2/ja active Active
-
2024
- 2024-02-07 JP JP2024016868A patent/JP2024054234A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202191745A1 (ru) | Катионные нейротоксины | |
TN2017000085A1 (en) | Polypeptide having a polyester degrading activity and uses thereof | |
CY1121891T1 (el) | Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας | |
EA201892386A1 (ru) | Химерные нейротоксины | |
EA201690314A1 (ru) | Анти-garp-белок и его применения | |
MX2020010262A (es) | Manufactura de neurotoxinas de clostridium botulinum recombinantes. | |
PH12015501983B1 (en) | Peptides and compositions for treatment of joint damage | |
ZA201506093B (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
MY167231A (en) | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same | |
TR201909037T4 (tr) | Yeni protein deamidaz. | |
MX2020002544A (es) | Sales de glicopirrolato. | |
BR112017019625A2 (pt) | udp-glicosiltransferases | |
MY181068A (en) | Recombinant microorganism for improved production of fine chemicals | |
EA201401211A1 (ru) | Улучшенные варианты фермента химозина | |
BR112017020308A2 (pt) | udp-glicosiltransferases | |
PH12017501678A1 (en) | Recombinant microorganism for improved production of finie chemicals | |
PH12014502763A1 (en) | Method for the degradation of keratin and use of the keratin hydrolysate produced | |
MD20150109A2 (ru) | Митохондриальные белковые конструкции и их использование | |
UY34662A (es) | Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas | |
MX2017008908A (es) | Proceso para la hidrólisis de queratina empleando proteasas. | |
PH12017502323A1 (en) | Novel xylanase | |
MX2018013556A (es) | Polipeptidos variantes con rendimiento mejorado y uso de los mismos. | |
MY168774A (en) | Endoglucanases with improved properties | |
EA201991474A1 (ru) | Способы получения фитоина | |
EA201691049A1 (ru) | Энтомотоксичные полипептиды |